

Influenza A(H3N2) egg-derived candidate vaccine viruses for development and production of vaccines for use in the 2017-2018 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or regional control authorities¹ approve the composition and formulation of vaccines used in each country.

02 March 2017 (*last updated 10 March 2017*)*

Candidate vaccine viruses (antigenically like A/Hong Kong/4801/2014)

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Victoria/673/2014	Wild type virus			VIDRL, Australia NIID, Japan FCI, UK
	NIB-92	Classical	NIBSC, UK	VIDRL, Australia NIID, Japan FCI, UK NIBSC, UK
A/New Caledonia/71/2014	Wild type virus			VIDRL, Australia NIID, Japan CDC, USA NYMC, USA
	NIB-91	Classical	NIBSC, UK	NIID, Japan NIBSC, UK
	IVR-178	Classical	Seqirus, Australia	VIDRL, Australia NIID, Japan FCI, UK NIBSC, UK CDC, USA
	X-257A	Classical	NYMC, USA	NIID, Japan NIBSC, UK CDC, USA NYMC, USA
A/Hong Kong/7127/2014	Wild type virus			NIID, Japan FCI, UK NIBSC, UK CBER, USA CDC, USA NYMC, USA

Table continued on page 2

***Reassortant NIB-94 is eventually not available. Thus it has been removed from the previous table dated on 02 March 2017.**

¹ http://www.who.int/immunization_standards/national_regulatory_authorities%20/offices/en/

Table continued from page 1

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Hong Kong/7127/2014	NIB-93	Classical	NIBSC, UK	NIID, Japan FCI, UK NIBSC, UK
	X-261	Classical	NYMC, USA	NIID, Japan FCI, UK NIBSC, UK CDC, USA NYMC, USA
A/Hong Kong/4801/2014	Wild type virus			NIID, Japan FCI, UK NIBSC, UK NYMC, USA CBER, USA CDC, USA
	X-263	Classical	NYMC, USA	NIID, Japan NIBSC, UK CDC, USA NYMC, USA
	X-263A	Classical	NYMC, USA	NIID, Japan FCI, UK NIBSC, UK CDC, USA NYMC, USA
	X-263B	Classical	NYMC, USA	NIID, Japan FCI, UK NIBSC, UK
A/Norway/2178/2014	NYMC X-273	Classical	NYMC, USA	NIBSC, UK NYMC, USA
A/Saitama/103/2014 (CEXP002)#	Wild type virus			NIID, Japan

NIID-MDCK cell (3 passages); Egg (28 passages)

Institutes contact details for candidate vaccine virus orders/information:

CBER: <http://www.fda.gov/cber>
CDC: xxu@cdc.gov
FCI: whocc@crick.ac.uk
NIBSC: standards@nibsc.org or enquiries@nibsc.org
NIID: flu-vaccine@nih.go.jp
NYMC: doris_bucher@nymc.edu
VIDRL: whoflu@influenzacentre.org

For general enquiries, please contact gisrs-whohq@who.int

Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag Lot number	Unitage (µgHA/ml)	Available from
	Candidate vaccine virus	Egg or cell			
A/New Caledonia/71/2014	X-257A	Egg	15/238	60	NIBSC, UK
			2015/107B	84	TGA, Australia
A/Hong Kong/4801/2014	NYMCX-263B	Egg	15/230	67	NIBSC, UK
	X-263B	Egg	2016/109B	112	TGA, Australia
	X-263	Egg	2016 AH3A	67	NIID, Japan
			2016 AH3B	61	NIID, Japan

Sheep Antisera

Purified HA from		Order number	Available from
Parent virus	Egg or Cell		
A/Hong Kong/4801/2014-like	Egg	16/182	NIBSC, UK
A/Hong Kong/4801/2014 (X-263B)	Egg	2016 AH3-1	NIID, Japan
		AS412	TGA, Australia
A/New Caledonia/71/2014 (X-257A)	Egg	AS410	TGA, Australia

Institutes contact details for candidate vaccine virus orders/information:

CBER: <http://www.fda.gov/cber>
CDC: xxu@cdc.gov
FCI: whocc@crick.ac.uk
NIBSC: standards@nibsc.org or enquiries@nibsc.org
NIID: flu-vaccine@nih.go.jp
NYMC: doris_bucher@nymc.edu
TGA: influenza.reagents@tga.gov.au
VIDRL: whoflu@influenzacentre.org

For general enquiries, please contact gisrs-whohq@who.int